Temozolomide (CCRG 81045)

Name: Temozolomide (CCRG 81045)
Brand: Selleck Chemicals
SKU: S1237
Rating: 5 (123 reviews)

For research use only.

Catalog No.S1237 Synonyms: NSC 362856,TMZ

123 publications

Temozolomide (CCRG 81045) Chemical Structure

CAS No. 85622-93-1

Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

Selleck's Temozolomide (CCRG 81045) has been cited by 123 publications

Cell Res, 2021, 10.1038/s41422-021-00528-3

PubMed: 34239070 ( click the link to review the publication )

Nature, 2020, 580(7804):517-523.

PubMed: 32322066 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Clin Cancer Res, 2021, clincanres.2092.2021

PubMed: 34426440 ( click the link to review the publication )

Theranostics, 2021, 11(4):1991-2005

PubMed: 33408794 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5776

PubMed: 34370292 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):164

PubMed: 33975615 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:683038

PubMed: 34195200 ( click the link to review the publication )

Hum Mol Genet, 2021, ddab193

PubMed: 34245265 ( click the link to review the publication )

Hum Mol Genet, 2021, ddab009

PubMed: 33438023 ( click the link to review the publication )

Front Oncol, 2021, 11:635472

PubMed: 33718225 ( click the link to review the publication )

Front Oncol, 2021, 11:638802

PubMed: 33869025 ( click the link to review the publication )

Neuropharmacology, 2021, 196:108717

PubMed: 34273388 ( click the link to review the publication )

Sci Rep, 2021, 11(1):20338

PubMed: 34645858 ( click the link to review the publication )

Cancer Gene Ther, 2021, 10.1038/s41417-021-00353-1

PubMed: 34059782 ( click the link to review the publication )

Neurochem Int, 2021, 147:105051

PubMed: 33979572 ( click the link to review the publication )

Int J Oncol, 2021, 59(2)64

PubMed: 34278448 ( click the link to review the publication )

Phytother Res, 2021, 10.1002/ptr.7061

PubMed: 33856743 ( click the link to review the publication )

Mol Med, 2021, 27(1):28

PubMed: 33765907 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2021, 10.1007/s00432-021-03678-4

PubMed: 34085099 ( click the link to review the publication )

Free Radic Res, 2021, 1-22

PubMed: 34323631 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Exp Ther Med, 2021, 21(2):175

PubMed: 33456542 ( click the link to review the publication )

J Biochem Mol Toxicol, 2021, e22848

PubMed: 34328678 ( click the link to review the publication )
Autophagy, 2021, 1-15

PubMed: 33629929 ( click the link to review the publication )

Oncol Rep, 2021, 45(4)34

PubMed: 33649855 ( click the link to review the publication )

J Clin Invest, 2020, 134132

PubMed: 33016930 ( click the link to review the publication )

Nat Commun, 2020, 11(1):550

PubMed: 31992716 ( click the link to review the publication )

J Clin Invest, 2020, 139542

PubMed: 33332283 ( click the link to review the publication )

J Thorac Oncol, 2020, 10.1016/j.jtho.2020.01.012

PubMed: 32004714 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2585.2020

PubMed: 33229458 ( click the link to review the publication )

Oncogene, 2020, 5

PubMed: 32372061 ( click the link to review the publication )

EBioMedicine, 2020, 59:102971

PubMed: 32846370 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):890

PubMed: 33087705 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 22;5(1):44

PubMed: 32317623 ( click the link to review the publication )

Cell Chem Biol, 2020, S2451-9456(20)30384-6

PubMed: 33113406 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(10):2001-2011

PubMed: 32737157 ( click the link to review the publication )

Aging (Albany NY), 2020, 29;12(2):1685-1703

PubMed: 32003751 ( click the link to review the publication )

Neuroendocrinology, 2020, 3

PubMed: 32241015 ( click the link to review the publication )

Mater Sci Eng C Mater Biol Appl, 2020, 108:110191

PubMed: 31923988 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15114

PubMed: 32150671 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(21)E8353

PubMed: 33171763 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3836

PubMed: 32123273 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Front Neurosci, 2020, 14:598266

PubMed: 33328869 ( click the link to review the publication )

Fluids Barriers CNS, 2020, 2;17(1):37

PubMed: 32487241 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(7):1659-1670

PubMed: 32279088 ( click the link to review the publication )

Transl Oncol, 2020, 13(1):70-78

PubMed: 31810002 ( click the link to review the publication )
PLoS One, 2020, 22;15(4):e0231470

PubMed: 32320427 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cancer Res, 2020, canres.132.2020

PubMed: 32680921 ( click the link to review the publication )

bioRxiv, 2020, 10.1101/2020.11.26.400234

PubMed: None ( click the link to review the publication )

Cell Signal, 2020, 71:109598

PubMed: 32165236 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):137

PubMed: 32677981 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:71

PubMed: 32165861 ( click the link to review the publication )

Theranostics, 2020, 10(7):3351-3365

PubMed: 32194873 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:65

PubMed: 32158355 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4529

PubMed: 31586101 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Autophagy, 2019, 15(6):1100-1111

PubMed: 30654687 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31810230 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

FASEB J, 2019, 33(12):13476-13491

PubMed: 31570001 ( click the link to review the publication )

Hum Mol Genet, 2019, 28(16):2738-2751

PubMed: 31087038 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz152

PubMed: 31518391 ( click the link to review the publication )

Eur J Pharm Biopharm, 2019, 136:156-163

PubMed: 30682492 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Endocrinology, 2019, 160(11):2600-2617

PubMed: 31322702 ( click the link to review the publication )

Cancer Commun (Lond), 2019, 39(1):81

PubMed: 31796105 ( click the link to review the publication )

Eur J Pharmacol, 2019, 852:42-50

PubMed: 30851271 ( click the link to review the publication )

J Oncol, 2019, 2019:1805841

PubMed: 31275377 ( click the link to review the publication )
Oncol Lett, 2019, 18(3):2509-2517

PubMed: 31402948 ( click the link to review the publication )

Anticancer Res, 2019, 39(12):6731-6741

PubMed: 31810938 ( click the link to review the publication )

Mol Imaging, 2019, 18:1536012119870899

PubMed: 31478435 ( click the link to review the publication )

Pharmaceutics, 2019, 11(8)E401

PubMed: 31405159 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(10):1203-1214

PubMed: 30202050 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2494

PubMed: 29950602 ( click the link to review the publication )

Genome Res, 2018, 28(8):1207-1216

PubMed: 29898900 ( click the link to review the publication )

Cancer Res, 2018, 78(23):6632-6642

PubMed: 30322863 ( click the link to review the publication )

J Control Release, 2018, 269:245-257

PubMed: 29162480 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 433:210-220

PubMed: 30008386 ( click the link to review the publication )

Mol Pharm, 2018, 15(2):609-618

PubMed: 29308904 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(5):777-790

PubMed: 29431617 ( click the link to review the publication )

Sci Rep, 2018, 8(1):7222

PubMed: 29740146 ( click the link to review the publication )

Int J Oncol, 2018, 52(1):295-304

PubMed: 29115581 ( click the link to review the publication )

Cell Cycle, 2018, 17(10):1199-1211

PubMed: 29886801 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1404-1415

PubMed: 29479863 ( click the link to review the publication )

J Pharm Sci, 2018, 107(3):922-933

PubMed: 29162424 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:7031-7040

PubMed: 30410360 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5607-5614

PubMed: 30344715 ( click the link to review the publication )

Medicines (Basel), 2018, 5(2)

PubMed: 29925764 ( click the link to review the publication )

J Neurooncol, 2018,

PubMed: 29564747 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(2):523-535

PubMed: 27440269 ( click the link to review the publication )
Clin Cancer Res, 2017, 23(20):6239-6253

PubMed: 28698200 ( click the link to review the publication )

Neuro Oncol, 2017, 20(2):236-248

PubMed: 29016925 ( click the link to review the publication )

Cell Syst, 2017, 4(6-:600-610

PubMed: 28601558 ( click the link to review the publication )

Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Oncol, 2017, 11(2):180-193

PubMed: 28098415 ( click the link to review the publication )

Hum Mol Genet, 2017, 26(22):4375-4387

PubMed: 28973155 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:691-702

PubMed: 27823879 ( click the link to review the publication )

Oncotarget, 2017, 8(12):18626-18639

PubMed: 28148893 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29865-29886

PubMed: 28415741 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(9):2282-2292

PubMed: 28687190 ( click the link to review the publication )

JCI Insight, 2017, 2(24)

PubMed: 29263302 ( click the link to review the publication )

J Clin Invest, 2016, 126(5):1801-14

PubMed: 27043280 ( click the link to review the publication )

Cancer Res, 2016, 76(1):139-49

PubMed: 26542214 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Eur J Pharm Biopharm, 2016, 104:7-18

PubMed: 27106606 ( click the link to review the publication )

Neurochem Res, 2016, 41(12):3192-3205

PubMed: 27632183 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41251-41264

PubMed: 27183910 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69961-69975

PubMed: 27564106 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79869-79884

PubMed: 27829215 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):11443-56

PubMed: 27006309 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):467-72

PubMed: 26163089 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142704

PubMed: 26571493 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(6):1555-65

PubMed: 24501391 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(12):1646-57

PubMed: 25482938 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(7):1740-7

PubMed: 23406775 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description

Features

Methazolastone is a second-generation alkylating agent.

Targets

DNA replication ^[1]
(L-1210, L-1210/BCNU cells)

In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.^[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. ^[2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. ^[3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. ^[4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Kelly	NX7GSpF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4\6S\|Q5KGh?		MXLJR\|UxRTF\|OT6yNQKBkcLz4pEJOU46PSEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
KellyCis83	M{LKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHnFTmo1QCCq		NVLXUWJFUUN3ME2yOVEvODEkgJpCtgKBkTF3Lke1JO69VQ>?	NXTFSGNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlAzQDJpPkK1PVYxOjh{PD;hQi=>
SK-N-AS	NEfnWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH:1N5g1QCCq		MUPJR\|UxRTJ{Nz63NQKBkcLz4pEJNlIvOTVizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
SK-N-ASCis24	NYPsOmF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnXhOFghcA>?		NF\ufXBKSzVyPUS4NE43OOLCidMx5qCKOTBzLkG1JO69VQ>?	M2DMW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
CHP-212	M4ToWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NILrVZg1QCCq		NGfn[XFKSzVyPUeuPVfjiIoEsfMAjVAvPjlizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
CHP-212Cis100	NVTUSVNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGnFbZQ1QCCq		MXfJR\|UxRTlwNUZihKnDueLCiUCuPFgh\|ryP	NHfxeJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2NFI5Oid-MkW5OlAzQDJ:L3G+
U87	NXrSdYdjTnWwY4Tpc44hSXO\|YYm=	NFXhV5QyODBizszN	NIfaPG4zPC15MjDo		NVvi[mtYcW6mdXPld{BF[1JzIHX4dJJme3Orb36=	M2SzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEC4PFY5Lz5{NUiwPFg3QDxxYU6=
LN229	M37od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33vNFAuPTBizszN			MWTJR\|UxRTF4IN88US=>	Mn;BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUCyO\|MoRjJ3N{WwNlc{RC:jPh?=
TR-LN229	Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWiwMVUxKM7:TR?=			M2PXWmlEPTB;N{eg{txO	Ml3aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUCyO\|MoRjJ3N{WwNlc{RC:jPh?=
U87	NVLsdZU3SXCxcITvd4l{KEG\|c3H5	M1vvSFDjiJN{MEFihKnDvU1?	M{HrRlI1KGh?		NHzPVI1mdmijbnPld{BEWSCrbnT1Z4VlKGGyb4D0c5Nqew>?	NUHCUo9URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PFE3PjhpPkK1OlgyPjZ6PD;hQi=>
U251MG	NEK2TlRCeG:ydH;zbZMhSXO\|YYm=	M{DvcFExOMLizszN	M4\NNlQ5KGh?	MlrCVGJU	NVHZcXBTcW6mdXPld{BieG:ydH;zbZM>	NVfGUpc4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PFA1PjRpPkK1OlgxPDZ2PD;hQi=>
U87MG	MnvVRZBweHSxc3nzJGF{e2G7	NX3DZnNoOTBywrFOwG0>	MW[0PEBp	NH3uPHZRSlN?	NFX4cXlqdmS3Y3XzJIFxd3C2b4Ppdy=>	NFmyfpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4NFQ3PCd-MkW2PFA1PjR:L3G+
U87	MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLGOVAuOzVyIN88US=>	MV[0POKhcMLi		NGDSb\|hqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|bHnnbJRtgQ>?	M4nqdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW0NlI{Lz5{NUW1OFIzOzxxYU6=
U118	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLoU4I2OC1\|NUCg{txO	NEXnTlE1QMLiaNMg		MYnpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=>	NVfNRnZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVQzOjNpPkK1OVU1OjJ\|PD;hQi=>
U87	MmCwSpVv[3Srb36gRZN{[Xl?	Mk\XNlUxNzN3MDFOwG0>	NUniXVd7PDkEoHlCpC=>		MWTlcohidmOnczDUUXgucW6mdXPl[EBxNVCNQz3wZY4h\GWlcnXhd4U>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NEKyN{c,OjV3NUSyNlM9N2F-
U118	MULGeY5kfGmxbjDBd5NigQ>?	NHrJVmszPTBxM{WwJO69VQ>?	MYC0POKhcMLi		MXzlcohidmOnczDUUXgucW6mdXPl[EBxNVCNQz3wZY4h\GWlcnXhd4U>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NEKyN{c,OjV3NUSyNlM9N2F-
U87	M2HEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLI[5EzPTBxM{WwJO69VQ>?	NV3pe\|RzPDkEoHlCpC=>		NYPLeZZqcW6lcnXhd4V{KHSqZTDw[ZJk\W62YXflJI9nKGOnbHzzJIlvKFNiYX7kJGczN04EoHPveJJm[XSnZDD3bZRpKFSPWB?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3NEKyN{c,OjV3NUSyNlM9N2F-
A375	NXTrfZdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYnDOXI3PDkEoHlCpC=>		NGfRVIFKSzVyPUK2OUDPxE1?	Mn\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
A2058	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFP6fZI1QMLiaNMg		MYTJR\|UxRTF{IN88US=>	M3jWUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUK0OVUzLz5{NUWyOFU2OjxxYU6=
M238	NWXZboxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUW0POKhcMLi		MVvJR\|UxRTRyIN88US=>	NYDONHFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlQ2PTJpPkK1OVI1PTV{PD;hQi=>
M249	NHTzcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnzSOFjDqGkEoB?=		NEXzOWtKSzVyPUK1OEDPxE1?	NIi3VJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyOFU2Oid-MkW1NlQ2PTJ:L3G+
M21	MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXO0POKhcMLi		NY\0[WZ6UUN3ME2yNlEh\|ryP	NHO1Tmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyOFU2Oid-MkW1NlQ2PTJ:L3G+
U251	M{TMVGN6fG:2b4jpeJkhSXO\|YYm=	NHTsZoszOCEQvF5CpC=>	NYjj[ohVPDkEoHlCpC=>		M4XoUZJm\HWlZXTzJJRp\SCyZYLj[Y51[WenczDv[kBkd2yxbnnld{Bnd3KvZXS=	MkfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{SzPFEoRjJ3NEO0N\|gyRC:jPh?=
LN229	MV3DfZRwfG:6aYT5JGF{e2G7	NEDE[JMzOCEQvF5CpC=>	MXK0POKhcMLi		M3;oS5Jm\HWlZXTzJJRp\SCyZYLj[Y51[WenczDv[kBkd2yxbnnld{Bnd3KvZXS=	NXvoepl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|Q{QDFpPkK1OFM1OzhzPD;hQi=>
U373MG-LUC	M1i2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnvLO\|IhcA>?		NXLyd4xJUUN3ME62NFAh\|ryP	NXK2fJpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|E6PTNpPkK1OFMyQTV\|PD;hQi=>
U87	MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLaPZQzPS1{MECg{txO	Ml22OFjDqGkEoB?=		MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	Mk\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEC3OFUoRjJ3NECwO\|Q2RC:jPh?=
U251	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTVRmkzPS1{MECg{txO	Ml;4OFjDqGkEoB?=		MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NH\IN3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSwNFc1PSd-MkW0NFA4PDV:L3G+
U251	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVixNFAuPDByIN88US=>	M4XtTFczNzl4IHi=		M3ztSpRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?=	MkDOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|N{WyO\|EoRjJ3M{e1NlcyRC:jPh?=
U373	MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYexNFAuPDByIN88US=>	M{\TXFczNzl4IHi=		NYGwS2dNfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN5NUK3NUc,OjV\|N{WyO\|E9N2F-
U343	NFq0WmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnYPHlROTByLUSwNEDPxE1?	MXS3Nk86PiCq		MUP0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:\|c4nwc4wh\W6qYX7j[YQhyqB?	M1fjTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{e1NlcyLz5{NUO3OVI4OTxxYU6=
U87MG-luc2	NIf1SlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWG2e3RlOTByLUSwNEDPxE1?	M{SyRlczNzl4IHi=		NHPBZYR1cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC=	NX7jVXVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO\|UzPzFpPkK1N\|c2OjdzPD;hQi=>
U87	NUfP[HlrTnWwY4Tpc44hSXO\|YYm=	NVXqeZVjOjByIN88US=>	M3rER\|Q5KGh?		MWDpcoNz\WG\|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v	NFrRSnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO\|czOSd-MkWzN\|c4OjF:L3G+
U251	MXrGeY5kfGmxbjDBd5NigQ>?	MkPHNlAxKM7:TR?=	MUe0PEBp		MoSxbY5kemWjc3XzJGJTS0N\|IH3SUmEh\XiycnXzd4lwdg>?	MnvrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|M{e3NlEoRjJ3M{O3O\|IyRC:jPh?=
A172	NFOydmVHfW6ldHnvckBCe3OjeR?=	MUiyNFAh\|ryP	NFX2Slg1QCCq		NXrlN5JNcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?=	NX3BZlVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
U251	NHnON5FHfW6ldHnvckBCe3OjeR?=	M3Ps[VIxOCEQvF2=	NIizWFM1QCCq		MWfpcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gRnJESTFuIFLSR2EzNCCUQVS1NUBidmRiRlHOR2Qz	NFu3PI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO\|czOSd-MkWzN\|c4OjF:L3G+
A172	MX7GeY5kfGmxbjDBd5NigQ>?	MnPZNlAxKM7:TR?=	NE\pN3k1QCCq		NXzqUlZpcW6lcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJI9nKEKUQ1GxMEBDWkODMjygVmFFPTFiYX7kJGZCVkOGMh?=	M{DOVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O\|IyLz5{NUOzO\|czOTxxYU6=
U87	MontSpVv[3Srb36gRZN{[Xl?	M3rzNVIxOCEQvF2=	NX7sRZhHOjRxN{KvNVIxKGh?		MonTbY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6	NFXXZ3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzO\|czOSd-MkWzN\|c4OjF:L3G+
U251	M1vkSWZ2dmO2aX;uJGF{e2G7	M2rqeFIxOCEQvF2=	NV\iToh6OjRxN{KvNVIxKGh?		M2TqNIlv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>?	NXyyWY8{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN\|c4OjFpPkK1N\|M4PzJzPD;hQi=>
A172	MXPGeY5kfGmxbjDBd5NigQ>?	MljZNlAxKM7:TR?=	M2\HUlI1Nzd{L{GyNEBp		M2HkOolv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>?	Mn3lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|M{e3NlEoRjJ3M{O3O\|IyRC:jPh?=
SNB19V	NFzHNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGTxdo04KGR?	M2XMXmROW09?	MmXWS2k2OD1\|NT63xtEyOiEQvF2=	M2LXSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
SNB19M	M{L6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVO3JIQ>	M3vWNWROW09?	MYTHTVUxRTR4OT65xtE5QCEQvF2=	NHHXeG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
SNB19VR	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWrM[2JZPyCm	MYDEUXNQ	MkTLS2k2OD1{OECuNuKyOThizszN	NVHFZ4doRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PDFpPkK1Nlc4PDRzPD;hQi=>
U373V	NITwWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX63JIQ>	NFTXdYZFVVOR	NVv6UHRJT0l3ME22PE4xyrF\|MjFOwG0>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
U373M	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2H5Zlch\A>?	NXjEOFhxTE2VTx?=	NE\Ue5ZIUTVyPUO2PE44yrF6NjFOwG0>	M4LqelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
U373VR	MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVXEVot7PyCm	NFm0UY5FVVOR	MYrHTVUxRTJ6OD64xtE{OyEQvF2=	MnHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
U87MG	NIe4[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NULNW5Y6PyCm	M4nRRmROW09?	MXPHTVUxRTN6LkRCtVIxKM7:TR?=	NILVVVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
HCT116	MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHvCbm84KGR?	MY\EUXNQ	Ml6zS2k2OD13N{muPeKyOzJizszN	NYDxU5VzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PDFpPkK1Nlc4PDRzPD;hQi=>
DLD1	NX;DVnVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVLUfmgzPyCm	NVHzdpl1TE2VTx?=	NFrkSpBIUTVyPUWwNU41yrF7MzFOwG0>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
MRC5	NV\z[\|QzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmPPO{Bl	NUTNRo5FTE2VTx?=	MYnHTVUxRTR2OT60xtE5KM7:TR?=	M4DYRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O\|Q1OTxxYU6=
SNB19V	M3KxWmZ2dmO2aX;uJGF{e2G7	MYixNFAh\|ryPwrDUUXo>	Ml62NE04OiCq		Mn7DbY5kemWjc3XzJO6{UDKDWDDlfJBz\XO\|aX;uJIJmfHenZX6gNVYh[W6mIEeyJIg>	NGTwW489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q1OSd-MkWyO\|c1PDF:L3G+
T98G	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXK5fXl6PS9zMD:xOUDPxE1?	NWj6[md6OjUEoHi=		NYnpb21ucW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wt[IVx\W6mZX70cJkh[W[2ZYKgZ49v[2:vaYThcpQufGWvb4rvcI9ucWSnIIfpeIghVlCnNj3QSHQ>	Ml30QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkK5OlEoRjJ3Mk[yPVYyRC:jPh?=
U251	M3\wT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVS1M\|ExNzF3IN88US=>	NVHiOoFROjUEoHi=		M1TNfolv\HWlZYOgZ4VtdCCmZXH0bEBld3OnLXTldIVv\GWwdHz5JIFnfGW{IHPvcoNwdWm2YX70MZRmdW:8b3zvcYll\SC5aYToJG5R\TZvUFTU	MlO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkK5OlEoRjJ3Mk[yPVYyRC:jPh?=
T98G	Mo\mSpVv[3Srb36gRZN{[Xl?	NILkUGQyPSEQvF2=	MmXHNlTDqGh?		NGWyOW1qdmO{ZXHz[ZMhTE6DLX\yZYdu\W62YYTpc44hcW5iTmDlOk1RTFRidILlZZRm\CCpbHnvcYEh[2WubIO=	NELVNIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2Nlk3OSd-MkWyOlI6PjF:L3G+
U251	MkTMSpVv[3Srb36gRZN{[Xl?	MXSxOUDPxE1?	NXjPS2d5OjUEoHi=		M4XPRYlv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4Mkm2NUc,OjV{NkK5OlE9N2F-
U-87 MG	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVy3NkBp		M3X6dWlEPTB;MD65N{BuVcLi	NI\EV4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK0OVM{Oid-MkWyOFU{OzJ:L3G+
U-118 MG	M2XKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXG3NkBp		NYLhOpE1UUN3ME2xMlA2KG2PwrC=	NXLHXYNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFU{OzJpPkK1NlQ2OzN{PD;hQi=>
U87	NF;HVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NU\3e3B7OjRiaB?=		NGjmTHhKSzVyPUK2NE4{PCEQvF5CpC=>	NHzTU209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG3N\|I{Oyd-MkWxO\|MzOzN:L3G+
U87 GSLCs	NIDSNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWLWZ\|ZIOjRiaB?=		MkLvTWM2OD15Nk[uNVEh\|ryPwrC=	M{\2W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUezNlM{Lz5{NUG3N\|I{OzxxYU6=
U87MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYS3NkBp		MULJR\|UxRTF3Lk[yOUDPxE4EoB?=	NVf2OmI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVA6OTVpPkK1NFUxQTF3PD;hQi=>
U251	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnafIVZOTByLUSwNEDPxE1?	M3m5VlQ5KGh?	NVjxXI5yTE2VTx?=	NXHnfFlYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NXjncnQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlM4OzZpPkK0OlI{PzN4PD;hQi=>
U87	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DyfVExOC12MECg{txO	M{GyclQ5KGh?	MV\EUXNQ	MkjKbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ{M{ezOkc,OjR4MkO3N\|Y9N2F-
MDA-MB-231-br	MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1O1d\|AuOTBizszN	MlfUOFghcA>?	NHLMVI5FVVOR	MYjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NVPsUnhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlM4OzZpPkK0OlI{PzN4PD;hQi=>
HCC-1937	M4KzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTZRmdyOC1\|MECg{txO	NVfFR2J1PDhiaB?=	MYrEUXNQ	M1PrR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NEnIZm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[yN\|c{Pid-MkS2NlM4OzZ:L3G+
MDA-MB-231	NGjiUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;Ze4gxNTRyIN88US=>	Mnr3OFghcA>?	NEPMdpNFVVOR	MofqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NFL2Xmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[yN\|c{Pid-MkS2NlM4OzZ:L3G+
MDA-MB-468	MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWiwMVUxOCEQvF2=	MlnXOFghcA>?	MoLRSG1UVw>?	NU\wVm82cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MkfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
T47D	M2D0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXUNE0yODBizszN	NUPoR2doPDhiaB?=	MVTEUXNQ	MkXMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MoHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
MCF7	M{jHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTSb5J1OC1zMECwJO69VQ>?	NVXxNldNPDhiaB?=	M{nrOWROW09?	NY\zOGkxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MmjTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N\|YoRjJ2NkKzO\|M3RC:jPh?=
Hs683	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{KzU\|AuOTByMDFOwG0>	M1npRlk3KGh?		NH;1bm1KSzVyPUGyPE46KM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7NUmwO{c,OjR2OUW5NFc9N2F-
U87	NIXNUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jEUFAuOTByMDFOwG0>	NXfJ[IhPQTZiaB?=		MVvJR\|UxRTF6LkS1JO69VQ>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7NUmwO{c,OjR2OUW5NFc9N2F-
LNZ308	M2\hT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DseVAuOTByMDFOwG0>	MlzHPVYhcA>?		MWnJR\|UxRTN{Nj63JO69VQ>?	NVnI[WJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVU6ODdpPkK0OFk2QTB5PD;hQi=>
U87	NF3qSGdCeG:ydH;zbZMhSXO\|YYm=	NFLDeGYyODBizszN	MkD0OFghcA>?	MVvEUXNQ	NVGwfI9UcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=>	NUnlVmZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFE2QDZpPkK0OFgyPTh4PD;hQi=>
U251	M4P3bWFxd3C2b4Ppd{BCe3OjeR?=	M{T4[FExOCEQvF2=	M1fHTFQ5KGh?	NG\NOmxFVVOR	M1fvNIlv[3KnYYPld{B1cGViY3HzdIF{\S1\|L{egZYN1cX[rdIm=	MmTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OEG1PFYoRjJ2NEixOVg3RC:jPh?=
U251	M4DrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2PCRVI1KGh?		NYH4NJB1UUN3ME24Ok4zQeLCidMx5qCKOS53ODFOwG0>	NG[1Tlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOlk2PCd-MkSzNlY6PTR:L3G+
U251	NGTTXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGCzNJE1QCCq		MUjJR\|UxRTd3LkO05qCKyrIkgJmxMlAzKM7:TR?=	NYrZfI1qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlY6PTRpPkK0N\|I3QTV2PD;hQi=>
U251	NFjwSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHzUdZI4OiCq		MXHJR\|UxRTd{LkSy5qCKyrIkgJmxMlQ2KM7:TR?=	M3KzZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K2PVU1Lz5{NEOyOlk2PDxxYU6=
U251	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF;zTJQ6PiCq		MlPKTWM2OD14OT64NwKBkcLz4pEJN{4xPCEQvF2=	M2DlcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K2PVU1Lz5{NEOyOlk2PDxxYU6=
T98G	MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrIO3AxNTd3MDFOwG0>	NUDPPWMxPzJxOU[gbC=>		MV\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M{jkeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K0NFgxLz5{NEOyOFA5ODxxYU6=
U251-MG	NEP5TW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml75NE05ODBizszN	NWPlbm1EPzJiaB?=		NUfGO41TcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{[zNEc,OjRyOUO2N\|A9N2F-
D54-MG	Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4[wflAuQDByIN88US=>	MkDHO\|IhcA>?		M2HTcIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7M{[zNEc,OjRyOUO2N\|A9N2F-
SHG-44	Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHHW3cyOC1{MECg{txO	Mny4PVYhcA>?		MoH3TWM2OD17LkezJOKyKDJwMUKg{txO	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
U373	M3r2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWqxNE0zODBizszN	NEHzTYY6PiCq		MXTJR\|UxRTFyLkGzJOKyKDFwMEKg{txO	MkLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkW1OlkoRjJ2ME[1OVY6RC:jPh?=
HT-29	MonkSpVv[3Srb36gRZN{[Xl?	M1u3cFUxOCEQvF2=	NFTLb20zPC92ODDo		MYnlcohidmOnczD0bIUhdGW4ZXzzJI9nKM7\|LViyRXjDqA>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB\|OEC2PEc,OjRyM{iwOlg9N2F-
PC-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfZNE0zPSEQvF2=	NH\TXZU1QCCq		M13ETIlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDwc5RmdnSrYYTl[EBjgSCueXPvdIVv\Q>?	NFSyVoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0Olk{PCd-MkO3OFY6OzR:L3G+
PC-3	MWDBdI9xfG:\|aYOgRZN{[Xl?	M1HKfFI2KM7:TR?=	M4fCfVQ5KGh?		NH7z[2xqdmS3Y3XzJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2NkmzOEc,OjN5NE[5N\|Q9N2F-
T98G	NHq4V2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWK1NE01ODBizszN	M1frOlE1PCCq		M4X1cYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NWrJelg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NVU1QTlpPkKzO\|E2PDl7PD;hQi=>
U87-MG	MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\mdYY6OTByINM1US=>	NHjZdmM4OiCq		MnnVbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>?	NYO2N4tFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PVY4QDhpPkKzOlk3Pzh6PD;hQi=>
U251-MG	NEHST4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XOb\|ExOCEEtV2=	NULySI1tPzJiaB?=		M3e1OYlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7Nke4PEc,OjN4OU[3PFg9N2F-
LNT-229	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;pN{0yODBizszN	MVOyOEBp		MlWxbY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M1TWTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nk[3OlMzLz5{M{[2O\|Y{OjxxYU6=
T98G	M{\xWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU[xNE04ODBizszN	MmrYNlQhcA>?		MmO2bY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NFrLU\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[2O\|Y{Oid-MkO2Olc3OzJ:L3G+
U87	M4O4ZmZ2dmO2aX;uJGF{e2G7	NH;pNZEyODBiwsXN	MVmzJIg>		M3v2WYVt\X[jdHXzJJRp\SCuZY\lcJMhd2ZicFPob\|Eh[W6mIIDDbIsz	MmPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke0OlkoRjJ\|Nk[3OFY6RC:jPh?=
HCT116	NWnJS\|dUTnWwY4Tpc44hSXO\|YYm=	NF\tXnoyODBiwsXN	NHfLXVA{KGh?		NXW1epB5cW6mdXPld{B1cGViQ3jrNUBRcG:\|cHjvdplt[XSrb36=	M3\4XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nk[3OFY6Lz5{M{[2O\|Q3QTxxYU6=
HCT3-6	NXuwUYo5TnWwY4Tpc44hSXO\|YYm=	Mon3NVAxKML3TR?=	MWWzJIg>		M3jjbolv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w	M1fFTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nk[3OFY6Lz5{M{[2O\|Q3QTxxYU6=
U-87	M1HLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYewMVQxKM7:TR?=	NVrtTo1COTJiZB?=		MWXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
U-87	NGH6WXFCeG:ydH;zbZMhSXO\|YYm=	NWDOb2pXOC12MDFOwG0>	MnLPN{83KGR?		NF;TV3NqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	NV7qcmVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OFU4OjlpPkKzOlQ2PzJ7PD;hQi=>
U-87	MVjGeY5kfGmxbjDBd5NigQ>?	NHrKN\|ExNTRyIN88US=>	M3jSVFMwPiCm		MlS3bY5lfWOnczDheZRweGijZ4mgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
GB-SCC010	M4DYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFj6UJU1KGR?		M3fBXmlEPTB;MkK2JO69VQ>?	NGH3fHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xNlc2PSd-MkO2NVI4PTV:L3G+
GB-SCC026	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NULnfmNnPCCm		MmDuTWM2OD13Mz6xJO69VQ>?	M1;ZZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkGyO\|U2Lz5{M{[xNlc2PTxxYU6=
GB-SCC028	M2\TdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVnkc\|JYPCCm		MoPyTWM2OD1zNkeg{txO	NULsWGp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVI4PTVpPkKzOlEzPzV3PD;hQi=>
U87	NWDFWmJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVjBbFI5PCCm		MkfzTWM2OD12NT6yJO69VQ>?	NF\aRpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xNlc2PSd-MkO2NVI4PTV:L3G+
U87 stem cell	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2[wRlQh\A>?		NXW2SZlLUUN3ME22Ok44KM7:TR?=	M{n0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkGyO\|U2Lz5{M{[xNlc2PTxxYU6=
TLX5 lymphoma	NWL6cXM6S3m2b4TvfIlkcXS7IHHzd4F6				MkHVTWM2OCB;IEWg{txO	NVjRRmFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{ezPVAxQCd-N{ezPVAxQDxxYU6=
GM892 A	MWDDfZRwfG:6aXPpeJkh[XO\|YYm=				M2HBWGlEPTBiPTC3MlYh\|ryP	M4POblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd5M{mwNFgoRjd5M{mwNFg9N2F-
TLX5 lymphoma	NICyT3dEgXSxdH;4bYNqfHliYYPzZZk>				MoTGTWM2OCB;IEWg{txO	NUfhVI9MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK0OVkxOTRpPkGyOFU6ODF2PD;hQi=>
HCT116	NYTFXGxkS3m2b4TvfIlkcXS7IHHzd4F6		M1n1flQh\GG7cx?=		NX6yT2xtUUN3MDC9JFQvOzRizszN	M1ixbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OECwPFA{Lz5zOUiwNFgxOzxxYU6=
SNB75	MmPJRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	M1flSFExKHWP	MUiyOEBpenN?		MnLoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVTlK3OUBk\WyuczDheEAyOCC3TTDh[pRmeiB{NDDodpMh[nliU2LCJIF{e2G7	MnzoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{Nki1NlYoRjJ{Mk[4OVI3RC:jPh?=
C6	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	NEnQeYIyODBidV2=	M2LIblQ5KGi{cx?=		M2fpO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgdoF1KEN4IHPlcIx{KGG2IEGwNEB2VSCjZoTldkA1QCCqcoOgZpkhdmW3dILhcEBz\WRiaX7jc5Jxd3KjdHnvckBie3OjeR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEWyOkc,OjJ{Nki1NlY9N2F-
SF295	Ml7URY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	MlLlNVAhfU1?	NF\SUWgzPCCqcoO=		M33abGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1[yPVUh[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeR?=	M33xdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Mk[4OVI3Lz5{MkK2PFUzPjxxYU6=
U87	MkLHRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWW1JIRigXN?		NHKySnlKSzVyIE2gOFkh\|ryP	NH;nOXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[wPFM5QSd-MkK2NFg{QDl:L3G+
U138MG	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=		MVG0PEBpenN?		MlXzTWM2OCB;IEK2JO69VQ>?	M3;M[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[5OlgzLz5{M{C2PVY5OjxxYU6=
C6	NWPiS3FJS3m2b4TvfIlkcXS7IHHzd4F6		M3LQTlQ5KGi{cx?=		Ml;yTWM2OCB;IEO0JO69VQ>?	NV3QWI1SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlk3QDJpPkKzNFY6Pjh{PD;hQi=>
A2780	MoLiRY51cXS3bX;yJIF{e2G7		NYKyO\|VKPSCmYYnz		NHrZUGRKSzVyIE2gPE42KM7:TR?=	M1LWbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEm1OlIxLz5{M{i5OVYzODxxYU6=
A2058	MlTjRY51cXS3bX;yJIF{e2G7		MmHUOUBl[Xm\|		MWPJR\|UxKD1iM{WuOUDPxE1?	Mnf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6OUW2NlAoRjJ\|OEm1OlIxRC:jPh?=
SNB19	MX3BcpRqfHWvb4KgZZN{[Xl?		MYi1JIRigXN?		NH3LOJdKSzVyIE2gN\|ch\|ryP	M{POeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEm1OlIxLz5{M{i5OVYzODxxYU6=
M8	NE\WWYhCeG:ydH;zbZMh[XO\|YYm=	M1XUNlUxKHSxIEGwNEB2VQ>?	MkjPOFghcHK\|		Mn3YTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCPODDj[YxteyCjc4Pld5Nm\CCjczDhdI9xfG:2aXOvcoVkem:2aXOgZ4VtdHNiYYSgOVAhfG9iMUCwJJVOKGGodHXyJFQ5KGi{czDifUBCWENvbHHi[Yxm\CCjbn7lfIlvKFZiYX7kJFcuSUGGIIP0ZYlvcW6pLXLhd4VlKG[ub4egZ5l1d22ndILpZ{BidmGueYPpdy=>	NGnJW2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
SK-MEL-30	M37WSGFxd3C2b4Ppd{Bie3OjeR?=	MXqxNFAhfU1?	NH36Zog1QCCqcoO=		NFzmW5JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGPLMW1GVC1\|MDDj[YxteyCjc4Pld5Nm\CCjczDhdI9xfG:2aXOvcoVkem:2aXOgZ4VtdHNiYYSgNVAxKHWPIHHmeIVzKDR6IHjyd{BjgSCDUFOtcIFj\WynZDDhco5mgGmwIG[gZY5lKDdvQVHEJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyC{ZXzheIl3\SC2bzDjc451em:u	NGTUO\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
SK-MEL-30	MmrKRZBweHSxc3nzJIF{e2G7	NX7kPHpvPTBidV2=	NYHXNIlLPDhiaILz		NIjsS\|ZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGPLMW1GVC1\|MDDj[YxteyCjc4Pld5Nm\CCjczDhdI9xfG:2aXOvcoVkem:2aXOgZ4VtdHNiYYSgOVAhfU1iYX\0[ZIhPDhiaILzJIJ6KEGSQz3sZYJmdGWmIHHucoV5cW5iVjDhcoQhPy2DQVSgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{KHKnbHH0bZZmKHSxIHPvcpRzd2x?	NWjzW5BqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlU5PzdpPkK0NVI2QDd5PD;hQi=>
MNT1	MoHpRZBweHSxc3nzJIF{e2G7	MUOxNFAhfU1?	MYi0PEBpenN?		MULJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE2QVEGgZ4VtdHNiYYPz[ZN{\WRiYYOgZZBweHSxdHnjM45m[3KxdHnjJINmdGy\|IHH0JFExOCC3TTDh[pRmeiB2ODDodpMh[nliQWDDMYxi[mWuZXSgZY5v\XirbjDWJIFv\CB5LVHBSEB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNicnXsZZRqfmVidH:gZ49vfHKxbB?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{NUi3O{c,OjRzMkW4O\|c9N2F-
MNT1	M3jqWWFxd3C2b4Ppd{Bie3OjeR?=	M{HsVFUxKHWP	MUe0PEBpenN?		NGrydGFKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF3OWFEh[2WubIOgZZN{\XO\|ZXSgZZMh[XCxcITveIlkN26nY4LveIlkKGOnbHzzJIF1KDVyIIXNJIFnfGW{IES4JIhzeyCkeTDBVGMudGGkZXzl[EBidm6neHnuJHYh[W6mIEetRWFFKHO2YXnubY5oNWKjc3XkJIZtd3diY4n0c41mfHKrYzDhcoFtgXOrczDy[YxifGm4ZTD0c{Bkd262cn;s	NFuwSZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
A2780	NYPPTVFJS3m2b4TvfIlkcXS7IHHzd4F6		NXi0cGdIPSCmYYnz		M1TRW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFUh\GG7czDifUBOXFRiYYPzZZk>	NIPXb3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFQyQCd-MkS5NFA1OTh:L3G+
A2780/CP70	MlrJR5l1d3SxeHnjbZR6KGG\|c3H5		NGjJeIk2KGSjeYO=		NVriNZRxS3m2b4TvfIlkcXS7IHHnZYlve3RiTV3SMYRm\mmlaXXueEBpfW2jbjDBNlc5OC:FUEewJINmdGy\|IHHmeIVzKDViZHH5d{BjgSCPVGSgZZN{[Xl?	M2fFS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOFE5Lz5{NEmwNFQyQDxxYU6=
GBM 047T	NX[yc\|k2SW62aYT1cY9zKGG\|c3H5	NUTLfVJSOjBidV2=	M{HQN\|EhfG9iMjD3[YVsew>?		M4HSRXR2dW:{aXPp[IFtKGWoZnXjeEBqdiCyYYTp[Y51KGSncnn2[YQhT0KPIEC0O3Qh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIH7leZJwe3CqZYLlJIZwem2jdHnvckBifCB{MDD1UUBi\nSncjCxJJRwKDJid3Xlb5Mh[nliM1SgeJVud3JiY3zvco9o\W6rYzDhd5NigQ>?	MmDUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NUW1N\|IoRjJ4M{W1OVMzRC:jPh?=
GBM 464T	NYe5bVB{SW62aYT1cY9zKGG\|c3H5	NXjTTohpOjBidV2=	MWexJJRwKDJid3Xlb5M>		NXj4T\|ZRXHWvb4LpZ4ll[WxiZX\m[YN1KGmwIIDheIlmdnRiZHXybZZm\CCJQl2gOFY1XCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gcoV2em:\|cHjldoUh\m:{bXH0bY9vKGG2IEKwJJVOKGGodHXyJFEhfG9iMjD3[YVseyCkeTCzSEB1fW2xcjDjcI9vd2enbnnjJIF{e2G7	M2D5V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{W1OVMzLz5{NkO1OVU{OjxxYU6=
U87MG	MnHlSpVv[3Srb36gZZN{[Xl?		MVyzJIhzew>?		NFHJe2hKdmS3Y4Tpc44hd2ZiRF7BJIFtc3muYYTpc44hcW5iaIXtZY4hXTh5TVegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hVjdvTXXkS{Bnd3KvYYTpc44h[W[2ZYKgN{BpenNiYomgUGMuVVNxTWOgZY5idHm\|aYO=	NUDaWHFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2NVQ1OTRpPkK3OlE1PDF2PD;hQi=>
U87MG	Mm\VRY51cXS3bX;yJIF{e2G7				NI\CcHpCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{BwenSqb4TvdIlk[WyueTD4[Y5w\3KjZoTl[EBqdiCKYYLsZY4hdnWmZTDtc5V{\SCkcnHpckBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gd4xwfyC2dX3vdkBoem:5dHigZZQhPTBidX3vcE9s\yxiaY[gZYRucW6rc4TldoVlKG:wY3Wg[IFqdHliZn;yJFUh\GG7cx?=	M{LIOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NkG0OFE1Lz5{N{[xOFQyPDxxYU6=
U87MG	MlL2RY51cXS3bX;yJIF{e2G7				M4LJcGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJI9zfGixdH;wbYNidGy7IIjlco9oemGodHXkJIlvKEijcnzhckBvfWSnIH3veZNmKGK{YXnuJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIH3veZNmKHO3co\peoFtKGG2IEWwJJVud2xxa3esJIl3KGGmbXnubZN1\XKnZDDvcoNmKGSjaXz5JIZweiB3IHThfZM>	NE\LTlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[xOFQyPCd-Mke2NVQ1OTR:L3G+
MDCK	MlvDR5l1d3SxeHnjbZR6KGG\|c3H5		NGnvWVMzPCCqcoO=		NEjtdpVEgXSxdH;4bYNqfHliYXfhbY5{fCCPRFPLJINmdGy\|IHX4dJJme3OrbnegZ4Fz[m:waXOgZY5pgWS{YYPlJFkh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhOjRiaILzJI1m[XO3cnXkJIFnfGW{IEeg[IF6eyC3bnTldkBvd3Kvb4jpZ{Bkd26maYTpc44h[nlibXX0bJlt\W6nIHLseYUhe3SjaX7pcoch[mG\|ZXSgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBie3OjeR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh{M{i3PUc,Ojd6MkO4O\|k9N2F-
MDCK	MUDDfZRwfG:6aXPpeJkh[XO\|YYm=		NUfKWFRYOjRiaILz		NGT4OHZEgXSxdH;4bYNqfHliYXfhbY5{fCCPRFPLJINmdGy\|IHX4dJJme3OrbnegZ4Fz[m:waXOgZY5pgWS{YYPlJFkh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhOjRiaILzJI1m[XO3cnXkJIFnfGW{IEeg[IF6eyC3bnTldkBpgXCxeHnjJINwdmSrdHnvckBjgSCvZYTofYxmdmViYnz1[UB{fGGrbnnu[{Bj[XOnZDDjcI9vd2enbnnjJJN2en[rdnHsJIF{e2G7	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh{M{i3PUc,Ojd6MkO4O\|k9N2F-
NB-EBc1	M{LNfpFJXFNiYYPzZZk>				NFzJTWJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	NYPWSm5mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
C6	NYDzeoxQS3m2b4TvfIlkcXS7IHHzd4F6		M3nieVQh\GG7cx?=		MkLMSWM2OCB;IEG2MlUh\|ryP	M4PieFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFgyOC9pPlPoSW1DVDxxYU6=
U87	NEHO[\|dEgXSxdH;4bYNqfHliYYPzZZk>		NHv4W244OiCqcoO=		MXvJR\|UxKD1iMUmuN\|gh\|ryP	NYDWbGdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDFyLze+R4hGVUKOPD;hQi=>
SNB19	NV;MO5lUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4HyS\|ch\GG7cx?=		Mnv4S2k2OCB;IEO1Mlch\|ryP	MmS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=
SNB19	M1Prdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mln4O{Bl[Xm\|		M1O2N2dKPTBiPTC0OU43KM7:TR?=	NFfpZ2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5OTBxJ{7DbGVOSkx:L3G+
U373	M37hZWZ2dmO2aX;uJIF{e2G7	MWSxNFAhfU1?	MX[3NkBpenN?		MoXwTY5lfWO2aX;uJI9nKGSxdXLs[UB{fHKjbnTl[EBFVkFiYoLlZYshcW5iZX3weJkhfmWldH;yJJRz[W6\|ZnXjeIVlKGi3bXHuJHU{PzNiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6g[4FudWFvSELBXEBt\X[nbDDheEAyODBidV2gZYZ1\XJiN{KgbJJ{KGK7IH\sc5ch[3m2b33leJJ6	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4NVAwLz6FaFXNRmw9N2F-
Glioma	M2[yNWFvfGm2dX3vdkBie3OjeR?=				NULGT2Q3SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhUG:vbzDzZZBq\W6\|IDjoeY1idiliR3zpc41iKGOnbHzzJJhmdm:pcnHmeIVlKGmwIITyZY5{\2WwaXOgcY92e2ViYYPz[ZN{\WRiYYOgcY92e2Vic4Xyeol3[Wx?	MlzwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pERK / ERK / p-p38 / p38; PubMed: 24436439 Stem Cells Transl Med Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression. DR5 / c-FLIP / Survivin / XIAP; PubMed: 24436439 Stem Cells Transl Med Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours.	24436439
Growth inhibition assay	Cell viability; PubMed: 25751281 Mol Pharm Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.	25751281
Immunofluorescence	Phalloidin / Phospho-H2A.X; PubMed: 27375225 Sci Rep Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). cleaved caspase-3; PubMed: 25663820 Cancer Cell Int Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).	27375225 25663820

In vivo

After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. ^[1]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: L-1210 and L-1210/BCNU cells
Concentrations: 0 μM -100 μM
Incubation Time: l hours
Method:
L-1210 and L-1210/BCNU cells are seeded at 0.2 × 10₄ cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 10₅ and 8 × 10₅/mL. Control growth is logarithmic in this range.

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
Dosages: 40 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	38 mg/mL warmed (195.72 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Temozolomide (CCRG 81045) SDF

Molecular Weight	194.15
Formula	C₆H₆N₆O₂
CAS No.	85622-93-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NSC 362856,TMZ
Smiles	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03796507	Withdrawn	Drug: Temozolomide	Glioma of Brain	University of Rochester\|National Institutes of Health (NIH)	September 1 2021	Early Phase 1
NCT04901702	Recruiting	Drug: Onivyde\|Drug: Talazoparib\|Drug: Temozolomide	Recurrent Solid Tumor\|Recurrent Ewing Sarcoma\|Recurrent Hepatoblastoma\|Recurrent Malignant Germ Cell Tumor\|Recurrent Malignant Solid Neoplasm\|Recurrent Neuroblastoma\|Recurrent Osteosarcoma\|Recurrent Peripheral Primitive Neuroectodermal Tumor\|Recurrent Rhabdoid Tumor\|Recurrent Rhabdomyosarcoma\|Recurrent Soft Tissue Sarcoma\|Recurrent Wilms Tumor\|Refractory Ewing Sarcoma\|Refractory Hepatoblastoma\|Refractory Malignant Germ Cell Tumor\|Refractory Malignant Solid Neoplasm\|Refractory Neuroblastoma\|Refractory Osteosarcoma\|Refractory Peripheral Primitive Neuroectodermal Tumor\|Refractory Rhabdoid Tumor\|Refractory Rhabdomyosarcoma\|Refractory Soft Tissue Sarcoma	St. Jude Children''s Research Hospital\|Pfizer\|Ipsen	June 9 2021	Phase 1\|Phase 2
NCT04893785	Not yet recruiting	Drug: Cabozantinib and Temozolomide	Lung Neuroendocrine Neoplasm\|GEP Neuroendocrine Tumor	National Cancer Institute Naples	June 2021	Phase 2
NCT04200066	Not yet recruiting	Drug: Temozolomide Tamoxifen Maprotiline	Glioblastoma\|Brain Tumor	University of Rochester	May 1 2021	Phase 1
NCT04610736	Recruiting	Drug: Temozolomide Oral Suspension	Pediatric Cancer	Orphelia Pharma\|ClinSearch	March 2021	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
Cisplatin (NSC 119875)

Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP, cis DDP, DDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine (LY-188011) HCl

Gemcitabine (LY-188011, NSC 613327) HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Oxaliplatin (NSC 266046)

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Bleomycin (NSC125066) sulfate

Bleomycin Sulfate (NSC125066) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine (LY-188011)

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
Fluorouracil (5-Fluorouracil, 5-FU)

Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.
Carboplatin (NSC 241240)

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Features:A DNA synthesis inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

Temozolomide (CCRG 81045)